Allianz SE Makes New $444,000 Investment in Genenta Science S.p.A. (NASDAQ:GNTA)

Allianz SE bought a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned about 0.56% of Genenta Science at the end of the most recent reporting period.

Genenta Science Trading Down 0.1 %

Shares of GNTA opened at $3.98 on Monday. Genenta Science S.p.A. has a 52-week low of $2.20 and a 52-week high of $7.28. The firm has a 50-day moving average price of $3.96 and a 200 day moving average price of $4.53.

Genenta Science Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.